James Morton - Concepedia

Author

James Morton

Also Known As

J Morton, J. MORTON, J. Morton, J.A. Morton, J.A.P. Morton, James A Morton, James A. Morton, James Morton, Robert A. Zierenberg

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Royal Brisbane and Women's Hospital Leeds Teaching Hospitals NHS Trust National Hospital Organization Sheba Medical Center Cancer Council Queensland

About

James Morton is an author at Royal Brisbane and Women's Hospital specializing in medicine, immunology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	367
2	Immunology	5	5	315
3	Health Sciences	3	3	225
4	Cellular Therapies	3	3	155
5	Cell Biology	1	1	32

James Morton

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Haematologica	2018	207
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy Timothy P. Hughes, Susan Branford, Deborah L. White, Blood	2008	177
Granulocyte–colony-stimulating factor (G-CSF)–primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF–mobilized peripheral blood stem cells James Morton, Cheryl Hutchins, Simon Durrant Blood	2001	177
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study Ajay K. Gopal, Stephen J. Schuster, Nathan Fowler, Journal of Clinical Oncology ImmunologyPathologyImmunotherapyHematological MalignancyOncology	2018	101
Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications Siok‐Keen Tey, Glen Kennedy, Deborah Cromer, PLoS ONE Cell TherapyImmunodeficienciesImmunologyTransplantation MedicineImmunotherapy	2013	92
Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease Glen Kennedy, Jason Butler, Robyn Western, Bone Marrow Transplantation InflammationMycophenolate MofetilTransplantationSoluble Tnfα InhibitorPharmacology	2006	59
Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF Geoffrey R. Hill, Edward S. Morris, Madonna Fuery, Biology of Blood and Marrow Transplantation	2006	41
Impact of stem cell donation modality on normal donor quality of life: a prospective randomized study Glen Kennedy, James Morton, Robyn Western, Bone Marrow Transplantation Quality Of LifeTransplantationMarrow TransplantationStem Cell TransplantationProspective Randomized Study	2003	41
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux Meletios Α. Dimopoulos, Darrell White, Lofti Benboubker, Blood	2017	35
Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF James Morton, Anthony B. Morton, Robert Bird, Leukemia Research Cell TherapyTransplantationMedicineStem Cell MobilizationStem Cell Transplantation	1997	32

Page 1